Pulmonx Corp Asset Resilience Ratio
Pulmonx Corp asset resilience ratio. Pulmonx Corp (LUNG) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LUNG defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pulmonx Corp (2018–2025)
Asset resilience ratio of Pulmonx Corp from 2018 to 2025. This chart shows how Pulmonx Corp's Asset Resilience Ratio has changed over time. Read Pulmonx Corp (LUNG) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pulmonx Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Pulmonx Corp.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Pulmonx Corp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Pulmonx Corp Industry Peers by Asset Resilience Ratio
Compare Pulmonx Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Pulmonx Corp Asset Resilience Ratio by Year (2018–2025)
Pulmonx Corp asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Pulmonx Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $129.29 Million | -- |
| 2024-12-31 | 18.78% | $30.58 Million | $162.85 Million | -0.10pp |
| 2023-12-31 | 18.87% | $33.55 Million | $177.78 Million | -1.47pp |
| 2022-12-31 | 20.34% | $39.40 Million | $193.68 Million | +6.92pp |
| 2021-12-31 | 13.42% | $31.56 Million | $235.17 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $263.71 Million | -- |
| 2019-12-31 | 25.37% | $13.58 Million | $53.53 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $15.01 Million | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more